{"drugs":["Silvadene","Silver Sulfadiazine","SSD","SSD AF","Thermazene"],"mono":{"0":{"id":"548830-s-0","title":"Generic Names","mono":"Silver Sulfadiazine"},"1":{"id":"548830-s-1","title":"Dosing and Indications","sub":[{"id":"548830-s-1-4","title":"Adult Dosing","mono":"<b>Burn:<\/b> TOPICAL, apply 1% cream in 1\/16-inch layer once or twice daily until healing or skin grafting"},{"id":"548830-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in children"},{"id":"548830-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no specific dosage adjustment of silver sulfADIAZINE is necessary; measurement of sulfADIAZINE levels may be indicated during prolonged use in patients with impaired renal function<\/li><li><b>hepatic impairment:<\/b> no specific dosage adjustment of silver sulfADIAZINE is necessary; serum sulfonamide levels should be monitored during prolonged use in patients with impaired hepatic function<\/li><\/ul>"},{"id":"548830-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Burn<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Wound care<br\/>"}]},"3":{"id":"548830-s-3","title":"Contraindications\/Warnings","sub":[{"id":"548830-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to silver sulfADIAZINE or any component of the product<\/li><li>pregnancy (approaching or at term); sulfonamides may cause kernicterus<\/li><li>preterm infants or newborns 2 months of age or younger<\/li><\/ul>"},{"id":"548830-s-3-10","title":"Precautions","mono":"<ul><li>blood dyscrasias (eg, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hemolytic anemia) may occur<\/li><li>CNS reactions may occur<\/li><li>cross-sensitivity with other sulfonamides may occur; if allergic reactions occur, consider potential hazards of continuing therapy<\/li><li>cutaneous reactions, life-threatening (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis [TEN], exfoliative dermatitis), may occur<\/li><li>fungal proliferation, in or below the eschar, may occur<\/li><li>gastrointestinal reactions may occur<\/li><li>glucose-6-phosphate dehydrogenase deficiency; hemolysis may occur<\/li><li>hepatic or renal impairment; accumulation may occur; discontinuation may be necessary<\/li><li>hepatitis or hepatocellular necrosis may occur<\/li><li>toxic nephrosis may occur<\/li><\/ul>"},{"id":"548830-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"548830-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"548830-s-4","title":"Drug Interactions","sub":[{"id":"548830-s-4-13","title":"Contraindicated","mono":"<ul>Methenamine (theoretical)<\/ul>"}]},"5":{"id":"548830-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme, Erythroderma, Mycosis, Skin necrosis, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Hemolytic anemia<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Hepatitis<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Renal:<\/b>Interstitial nephritis, Nephrotoxicity<\/li><\/ul>"},"6":{"id":"548830-s-6","title":"Drug Name Info","sub":{"0":{"id":"548830-s-6-17","title":"US Trade Names","mono":"<ul><li>SSD AF<\/li><li>Silvadene<\/li><li>Thermazene<\/li><li>SSD<\/li><\/ul>"},"2":{"id":"548830-s-6-19","title":"Class","mono":"<ul><li>Antibacterial<\/li><li>Sulfonamide<\/li><\/ul>"},"3":{"id":"548830-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"548830-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"548830-s-7","title":"Mechanism Of Action","mono":"<ul><li>Topical: Bactericidal for many gram-positive and gram-negative organisms. Mechanism of action differs from that of silver nitrate or sodium sulfADIAZINE. Acts only on the cell membrane and cell wall. <\/li><li>Also active against yeasts and Candida albicans (M. albicans). <\/li><\/ul>"},"9":{"id":"548830-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>apply under sterile conditions<\/li><li>burn areas should be covered at all times with cream; reapply whenever necessary<\/li><li>reapply immediately after hydrotherapy<\/li><li>dressings are not required but may be used<\/li><\/ul>"},"10":{"id":"548830-s-10","title":"Monitoring","mono":"<ul><li>reduced ulcer<\/li><li>evidence of wound closure<\/li><li>CBC<\/li><li>renal function<\/li><li>serum sulfa levels<\/li><li>urinalysis for possible crystalluria (sulfa crystals)<\/li><\/ul>"},"11":{"id":"548830-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Silvadene<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>SSD<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Thermazene<\/b><br\/>Topical Cream: 1 %<br\/><\/li><\/ul>"},"12":{"id":"548830-s-12","title":"Toxicology","sub":[{"id":"548830-s-12-31","title":"Clinical Effects","mono":"<b>SULFONAMIDES<\/b><br\/>OVERDOSE: Data limited. Effects may be an extension of adverse events reported with sulfonamides. Methemoglbinemia has been reported after overdose. ADVERSE EVENTS: Adverse reactions to sulfonamides can involve nearly every organ system; many effects appear to be hypersensitivity reactions, and are dose related. DERMATOLOGIC: Various dermatological reactions, including rash, pruritus, erythema nodosum, and quite severe and often fatal erythema multiforme of the Stevens-Johnson type have been reported. Lyell's Syndromes are usually associated with the use of a long-acting sulfonamides. GASTROINTESTINAL: Nausea and vomiting are common. HYPERSENSITIVITY REACTION: Transient myopia, conjunctivitis, hepatic injury, and keratitis may occur in association with a hypersensitivity reaction. NEUROLOGIC: Headache, depression, and hallucinations have been reported with therapy.  <br\/>"},{"id":"548830-s-12-32","title":"Treatment","mono":"<b>SULFONAMIDES <\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Hypersensitivity reaction: For signs and symptoms of anaphylaxis administer oxygen, establish an airway, and give epinephrine and diphenhydramine as indicated.<\/li><li>Hypotensive episode: IV isotonic fluids at 10 to 20 mL\/kg, dopamine, norepinephrine.<\/li><li>Methemoglobinemia: Obtain a methemoglobin level. Treat symptomatic methemoglobinemia (usually at methemoglobin levels above 20% to 30%) with methylene blue and oxygen therapy.<\/li><li>Seizure: Seizures have been reported infrequently. Give benzodiazepines, barbiturates as indicated.<\/li><li>Monitoring of patient:  Obtain a baseline CBC, electrolytes including glucose level and hepatic enzymes and renal function tests.<\/li><\/ul>"},{"id":"548830-s-12-33","title":"Range of Toxicity","mono":"<b>SULFONAMIDES<\/b><br\/>TOXICITY: Methemoglobinemia has been reported after ingestion of 15 g sulfamethoxazole. Many of the adverse effects related to sulfonamides are hypersensitivity reactions, that develop at therapeutic doses.  The incidence of adverse effects increases with higher doses. THERAPEUTIC DOSE: Varies by agent.<br\/>"}]},"13":{"id":"548830-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to avoid using this medicine on newborn infants under 2 months of age.<\/li><li>This drug may cause pruritus or skin irritation.<\/li><li>Advise patient to apply drug to skin only. Patient should avoid exposure of cream to the eyes.<\/li><li>Instruct patient on proper skin or wound preparation prior to application of drug.<\/li><\/ul>"}}}